本帖最后由 老马 于 2012-1-13 21:20 编辑 , |/ O4 g) C6 E" {* S1 {' [1 Q) ^
3 J$ F4 y; u. f, t1 V
爱必妥和阿瓦斯丁的比较- \. S0 R& ?* M
/ }/ T" p4 p2 `7 a! ?& h5 k. b
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
& F+ W7 z' u w- b3 }* d
5 Q* V: H6 Y- _
$ @# k. K. M) Z
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
: t3 Y. r- D/ G& b% ~3 @+ O==================================================
k! d" b$ S0 ~: G( OOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, p0 e( }9 @8 SPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" O5 h/ q) q( X4 i" d- I9 \2 Q- eResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." Z* W! N e n- I' [
|